About this item:

449 Views | 478 Downloads

Author Notes:

Saad B. Omer somer@emory.edu, Hubert Department of Global Health, CNR 7017, Rollins School of Public Health, Emory University, 1518 Clifton Rd NE, Atlanta, GA 30322, USA

RAB, EAW, and SBO conceived the project. RAB was the technical lead for the project team, working with the app developer on all technical requirements, and drafted the manuscript.

PMF and DAS oversaw the development of information content and reviewed initial versions of the app during development. SBO supervised and oversaw the overall project.

All authors have read and contributed to the drafting of the manuscript and approved the final version.

Portions of this manuscript have been presented in poster form at the 2015 ID Week meeting, San Diego CA, October 2015.

The authors have no conflicts of interest to disclose. Go to:

Subjects:

Research Funding:

This project was supported by Centers for Disease Control and Prevention (CDC) grant #5P01TP000300 for the Emory University Preparedness and Emergency Response Research Center.

Its contents are solely the responsibility of the authors and do not necessarily represent the official views of CDC.

Keywords:

  • Science & Technology
  • Life Sciences & Biomedicine
  • Biotechnology & Applied Microbiology
  • Immunology
  • app
  • smartphone
  • vaccination
  • vaccine
  • IMMUNIZATION PROGRAM MANAGERS
  • WASHINGTON-STATE
  • UNITED-STATES
  • INFLUENZA

ReadyVax: A new mobile vaccine information app

Tools:

Journal Title:

Human Vaccines and Immunotherapeutics

Volume:

Volume 13, Number 5

Publisher:

, Pages 1149-1154

Type of Work:

Article | Final Publisher PDF

Abstract:

Published with license by Taylor & Francis © 2017, © Robert A. Bednarczyk, Paula M. Frew, Daniel A. Salmon, Ellen Whitney, and Saad B. Omer.Vaccine information of varying quality is available through many different sources. We describe the creation, release and utilization of ReadyVax, a new mobile smartphone app providing access to trustworthy, evidence-based vaccine information for a target audience of healthcare providers, pharmacists, and patients (including parents of children). We describe the information content and technical development of ReadyVax. Between the hard launch of the app on February 12, 2015 and October 8, 2016, the app has been downloaded by 5,142 unique users, with 6,841 total app sessions initiated, comprising a total of 15,491 screen views (2.3 screens/session on average). ReadyVax has been downloaded by users in 102 different countries; most users (52%) are from the United States. We are continuing outreach efforts to increase app use, and planning for development of an Android-compatible version of ReadyVax, to increase the available market for the app.

Copyright information:

© 2017 The Author(s).

This is an Open Access work distributed under the terms of the Creative Commons Attribution-Noncommercial 3.0 Unported License (http://creativecommons.org/licenses/by-nc/3.0/).

Creative Commons License

Export to EndNote